UroGen Pharma

UroGen Pharma, based in Princeton, NJ, the United States, is a pharmaceutical company listed as NASDAQ: URGN. UroGen Pharma develops treatments for urothelial and specialty cancers, including its FDA-approved therapies Zusduri and Jelmyto, based on its proprietary RTGel reverse-thermal hydrogel technology. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (3 in phase 3), testing UGN-103, UGN-102 and UGN-104 in bladder & urothelial cancer. The largest, NCT05243550 (A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer), plans to enrol 240 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.